Many studies have demonstrated the efficacy of partial or complete OPN inhibition in a variety of preclinical models of diseases, including CH [15,37,39], coronary artery disease [24,28,58,59], DCM [46], diabetic cardiomyopathy [48], heart failure [52], and cardiac fibrosis [13,15,38,39,60]. Here, SPP1 is linked to heart failure.